Non-fucosylated Anti-Human PD-L1 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ44] (CAT#: BioBet-044ZP) Datasheet

Target
PD-L1
Isotype
Whole Humanized Antibody
Description
ADCC-enhanced Atezolizumab is a non-fucosylated anti-PD-L1 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-PD-L1 Atezolizumab, a biobetter by reducing fucosylation of the Fc region of Atezolizumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Bladder cancer
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
FDA-approved

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD274
Full Name
CD274 molecule
Background
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and nonhematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin Vlike and Clike domains. Interaction of this ligand with its receptor inhibits Tcell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic Tcell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Alternative Names
B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1
Gene ID
Cellular Localization
Plasma membrane, Endosome
HGNC
OMIM
Involvement in Disease
Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Post-translational modifications
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Trade name
Tecentriq
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB11595
CAS number
1380723-44-3
Antibody Isotype
Humanized IgG1
Antibody Clone
Atezolizumab
Description
Atezolizumab (trade name Tecentriq) is a humanized monoclonal antibody that specifically targets cell death ligand 1 (PD-L1) programmed for proteins expressed on the surface of tumors. Atezolizumab was approved by the FDA on October 18, 2016 to prevent the interaction of PD-L1 and PD-1 and eliminate the inhibitory effect on the immune response seen in some cancers.
Indication
Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma
Synonyms
MPDL3280A
UNII
52CMI0WC3Y

Atezolizumab is a humanized IgG antibody that binds PD-L1 and prevents the interaction of programmed cell death protein 1 (PD-1) and B7-1. PD-L1 can be highly expressed on certain tumors, especially bladder cancer, which is thought to lead to reduced activation of immune cells (especially cytotoxic T cells). Preventing the interaction of PD-L1 and PD-1 can eliminate the inhibitory effect on immune response (such as anti-tumor immune response), thereby triggering anti-tumor response.

Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK